Keywords: cv, therapeutics, biogen, begin, cvt-124, phase, ii

CV Therapeutics And Biogen Begin CVT-124 Phase II

Article | 21 April 1997

Print This

- CV Therapeutics and Biogen have begun a Phase II study with theselective adenosine A(1)-antagonist, CVT-124, in patients with congestive ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in